CG Labz
Peptide Library / Growth Hormone / Performance

CJC-1295 (no DAC / Mod GRF 1-29)

Modified GRF (1-29)

CJC-1295 (Mod GRF 1-29) Research Protocol

Complete Research Guide 5 min read3 peer-reviewed references

Quickstart Overview

CJC-1295 is a tetra-substituted analog of GHRH (1-29) engineered for resistance to DPP-IV degradation. The no-DAC form (Mod GRF 1-29) produces a sharp, physiological GH pulse; the DAC form binds albumin for a 6–8 day half-life.

Reconstitution
Add 2.0 mL bacteriostatic water to a 5 mg vial → 2.5 mg/mL
Literature Range (no DAC)
100–200 mcg per administration, 1–3× daily
Literature Range (with DAC)
1–2 mg once or twice weekly
Measuring Reference
At 2.5 mg/mL: 100 mcg = 0.04 mL = 4 units
Route (studies)
Subcutaneous
Cycle Length
8–12 weeks

Scientific Data

Molecular Formula
—
Molecular Weight
3367.9 Da
Sequence
(D-Ala2,Gln8,Ala15,Leu27)-GRF(1-29)
Sequence Length
16
CAS
Research compound
Peptide Family
GHRH analog
Half-life
Refer to published literature
Solubility
Bacteriostatic water, sterile saline
Storage
Lyophilized: -20°C. Reconstituted: 2–8°C, use within 2–4 weeks.
Appearance
White lyophilized powder
Standard: 5 mg vial · 2 mL diluent

Dosing & Reconstitution Guide

Interactive Reconstitution
Adjust vial size, diluent and target dose. Results update live.
Full Precision Calculator →
Concentration
2.50 mg/mL
Draw Volume
0.040 mL
Syringe Units
4.0 U
Doses / Vial
50

Units assume a U-100 insulin syringe (100 units = 1 mL). Mod GRF 1-29 degrades faster in solution than most peptides — use within 2–3 weeks.

Frequency: 1–3× daily (no DAC) · 1–2× weekly (DAC)

Reconstitution Steps

  1. 1Bring vial to room temperature; swab stoppers.
  2. 2Add 2.0 mL bacteriostatic water slowly down the glass.
  3. 3Swirl gently; solution should be completely clear.
  4. 4Label and refrigerate immediately.

Supplies Needed

Planning example for a 12-week no-DAC protocol at 100 mcg twice daily, paired with Ipamorelin.

Peptide (5 mg vials)
12 weeks ≈ 3.4 vials (200 mcg/day)
Bacteriostatic Water
One 30 mL vial
Insulin Syringes (U-100)
168 (2/day) — or shared with Ipamorelin draw
Alcohol Swabs
2 per administration

Protocol Overview

Goal
Amplify endogenous GH pulse amplitude via GHRH-receptor stimulation.
Schedule
Daily (no DAC) or weekly (DAC), 8–12 weeks.
Dose Range
100–200 mcg per dose (no DAC); 1–2 mg/week (DAC).
Saturation
100 mcg is the approximate saturation dose per literature; higher doses yield diminishing returns.

Dosing Protocol

Start
100 mcg once daily before sleep
Increase
Add fasted AM and/or post-training doses
Target Range
100 mcg, 2–3× daily
Frequency
Match timing to Ipamorelin if stacked
Cycle Length
8–12 weeks on, 4 weeks off
Timing
Fasted; avoid carbohydrates/fats 2 h before and 30 min after

Storage Instructions

Lyophilized
−20 °C long term
Reconstituted
2–8 °C, use within 2–3 weeks
Light
Protect from light; this analog is light-sensitive

Important Notes

  • The DAC (Drug Affinity Complex) version produces continuous GH elevation ("GH bleed") rather than pulses — a different research model entirely.
  • Saturation occurs ≈ 100 mcg; doubling the dose does not double the response.
  • Extremely sensitive to improper storage — degraded Mod GRF loses efficacy rapidly.
  • Monitor IGF-1 and fasting glucose in extended protocols.

How This Works

Four amino-acid substitutions (D-Ala2, Gln8, Ala15, Leu27) protect the GHRH (1-29) backbone from DPP-IV cleavage and oxidation, extending its half-life from minutes to ~30 minutes (no DAC). It binds GHRH receptors on somatotroph cells, elevating cAMP and triggering GH synthesis and release. Because it acts on the GHRH pathway rather than the ghrelin pathway, it is additive with GHS-R agonists like Ipamorelin. The DAC variant adds a maleimidoproprionic acid linker that covalently binds serum albumin, extending half-life to approximately 6–8 days.

Potential Benefits & Side Effects

Reported in research
  • Amplified GH pulse amplitude in a physiological pattern
  • Elevated IGF-1 sustained for days (DAC form)
  • Improved body composition in animal studies
  • Enhanced sleep quality and recovery markers
  • Synergy with Ipamorelin — the most-cited secretagogue stack
Possible considerations
  • Flushing and head rush immediately after administration
  • Water retention, especially with DAC form
  • Injection-site redness or welts
  • Headache and dizziness
  • Carpal-tunnel-like symptoms at high doses

Lifestyle Factors

  • Fasted timing is non-negotiable for GHRH analogs
  • Avoid high-glycemic meals near doses; somatostatin surges blunt effect
  • Sleep hygiene amplifies the nightly GH pulse

Injection Technique

  1. 1Subcutaneous abdominal; may be drawn into the same syringe as Ipamorelin.
  2. 2Inject slowly; this analog can produce transient site redness.
  3. 3Rotate sites.

Frequently Asked Questions

Third-party HPLC testing

CG Labz Verified Batches

No published batches yet.

Research Disclaimer

All compounds are supplied strictly for laboratory research. Dosing figures below summarize ranges reported in published preclinical and clinical literature for reference purposes only. CG Labz does not provide medical advice or individualized dosing recommendations.

Peer-reviewed literature

References

  1. [1] Journal of Clinical Endocrinology & Metabolism
    Teichman S.L. et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
    View Source
  2. [2] Journal of Clinical Endocrinology & Metabolism
    Ionescu M. & Frohman L.A. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.
    View Source
  3. [3] Endocrinology
    Jetté L. et al. hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.
    View Source